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Abstract  
Objective: Grey matter (GM) damage and meningeal inflammation have been associated with early 
disease onset and a more aggressive disease course in Multiple Sclerosis (MS), but can these 
changes be identified in the patient early in the disease course?  
Methods: To identify possible biomarkers linking meningeal inflammation, GM damage and 
disease severity, gene and protein expression were analysed in meninges and CSF from 27 post-
mortem secondary progressive MS (SPMS) and 14 control cases. Combined cytokine/chemokine 
CSF profiling and 3T-MRI were performed at diagnosis in two independent cohorts of MS patients 
(35 and 38 subjects) and in 26 non-MS patients.  
Results: Increased expression of pro-inflammatory cytokines (IFNγ, TNF, IL2 and IL22) and 
molecules related to sustained B-cell activity and lymphoid-neogenesis (CXCL13, CXCL10, LTα, 
IL6, IL10) was detected in the meninges and CSF of post-mortem MS cases with high levels of 
meningeal inflammation and GM demyelination. Similar pro-inflammatory patterns, including 
increased levels of CXCL13, TNF, IFNγ, CXCL12, IL6, IL8 and IL10, together with high levels of 
BAFF, APRIL, LIGHT, TWEAK, sTNFR1, sCD163, MMP2 and pentraxin III, were detected in the 
CSF of MS patients with higher levels of GM damage at diagnosis.  
Interpretation: A common pattern of intrathecal (meninges and CSF) inflammatory profile 
strongly correlates with increased cortical pathology, both at time of the diagnosis and of death. 
These results suggest a role for detailed CSF analysis combined with MRI, as a prognostic marker 
for more aggressive MS. 
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 INTRODUCTION 
Disability progression in MS patients is accompanied by the accumulation of chronic white 
matter (WM) demyelination with limited repair, axonal loss, diffuse inflammatory changes in the 
normal appearing WM1,2 and both focal and diffuse cortical grey matter (GM) demyelination and 
neurodegeneration3–6. Neuroimaging has confirmed that cortical lesions and GM atrophy are 
strongly related to physical disability7–9 and that these are present from the earliest stages of the 
disease4,10,11 suggested that leptomeningeal immune cell infiltration and compartmentalized 
inflammation within the subarachnoid space may play a key role in the pathogenesis of this cortical 
pathology5,11,15-17. Increased meningeal inflammation is associated with a gradient of neuronal, 
astrocyte and oligodendrocyte damage and with microglial activation, which was higher in the 
superficial cortical layers (I-III)5,14. A strong association between meningeal inflammation and the 
severity of underlying pathology is also seen in the spinal cord and cerebellum, in primary 
progressive MS and in the brain biopsies of patients with a recent diagnosis of MS11,18–20 
.
  
Early in vivo detection of cortical pathology is vital in order to be able to effectively target 
the underlying mechanisms of progressive disease before significant disability develops. Cortical 
pathology could potentially be a biomarker indicating underlying compartmentalised inflammation. 
However, the in vivo detection of cortical lesions using MRI is still sub-optimal21,22 despite several 
improvements including the introduction of GM specific pulse sequences8,21,23–25 at high field 3T 
and ultra-high field 7T MRI26,27. Therefore, there is a need for additional surrogate biomarkers of 
cortical GM demyelination and neurodegeneration and compartmentalised meningeal inflammation 
in order to identify early in the disease course those individuals at risk of a more severe disease 
course.  
Several fluid biomarker studies have revealed the differential expression of individual CSF 
proteins in MS compared to controls. The presence of high levels of the neurofilament light-chain 
(NFL) protein is associated with a higher risk of conversion to clinically definite MS and/or 
increased brain and spinal cord atrophy28. Increased levels of pro-inflammatory cytokines and 
chemokines, such as CXCL1329, CXCL1229, TNF30,31, and IFNγ32 are detected in the CSF of MS 
patients. However, an association between the presence of these or other inflammatory mediators in 
the CSF, and increased GM pathology and clinical outcomes has not yet been shown. Our previous 
studies using post-mortem analysis of paired CSF and meningeal samples, obtained from MS cases 
with or without meningeal lymphoid like tissues15, has suggested that increased TNF and IFNγ 
expression is associated with more severe cortical pathology.  
Here we undertook a systematic and more comprehensive analysis of inflammatory and 
cytotoxic molecules expressed in the meninges and CSF derived from 27 post-mortem secondary 
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progressive MS (SPMS), stratified according to the level of meningeal inflammation and cortical 
demyelination, and 14 controls. This was then compared with the profile of inflammation related  
molecules in diagnostic CSFs in two independent cohorts of patients with MS, stratified by the 
presence of low or high numbers of cortical lesions determined by 3D-DIR MRI imaging, a training 
set (TS: 35 subjects) and a validation set (VS: 38 subjects), with the overall aim of determining 
whether cytokine profiles indicating greater cortical damage and a more rapidly progressive disease 
course could also be found in newly diagnosed MS patients. 
 
 
 
METHODS 
 
Study populations and subgroup classification 
 
Post-mortem MS and control cohort  
Snap frozen tissue blocks from 27 SPMS and 14 non-MS control (Ctrl) (without any 
evidence of neuropathology) post-mortem brains (Table 1) were obtained from the UK MS Society 
Tissue Bank at Imperial College (Ethical approval: National Research Ethics Committee: 
08/MRE09/31). Three snap frozen cortical tissue blocks (2x2x1cm), representative of different 
regions of the frontal and temporal cortex, were examined from every SPMS case and were 
screened for the presence and extent of GM demyelination and the degree of meningeal 
inflammation6,14,33. Fifteen SPMS cases were classified by a low level of meningeal inflammation 
and demyelination (PM-MSlow) and 12 by a high level of meningeal inflammation and 
demyelination (PM-MShigh), as previously described6. The degree of meningeal inflammation was 
assessed by manually counting the number of haematoxylin stained cell nuclei in 2 meningeal 
infiltrates for each examined tissue block (Fig 1A). The presence and extent of subpial (type III) 
GM demyelination was then assessed in all tissue blocks using immunohistochemistry for myelin 
oligodendrocyte glycoprotein (MOG) and the percentage of demyelinated GM with respect to the 
total GM calculated (Fig 1B) following the procedures previously optimized14. Not all MS and 
control cases from which the meningeal RNA had been prepared also had a paired CSF sample 
available. Therefore, for the CSF analysis, we included further samples from cases of SPMS for 
which the degree of inflammation and demyelination had been assessed in the same way (for details 
see Table 1).   
 
MS patient cohorts  
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Seventy-eight consecutive treatment naïve relapsing remitting MS patients from the MS 
Centre of Verona University Hospital (Italy) were screened at diagnosis between September 2014 
and February 2015. A first Training set (TS) cohort comprising 35 RRMS patients was enrolled. 
Inclusion criteria were the presence of at least 10 cortical lesions or less than 2 cortical lesions that 
permitted the stratification of the cohort into two subsets (TS-MShigh and TS-MSlow). Forty-three 
patients were excluded as that they did not meet the inclusion criteria. 
A second independent group of 38 treatment naïve MS patients (Table 2) from the MS 
Centre of Verona University Hospital (29 patients) and the MS Centre of Montichiari (9 patients) 
were consecutively recruited (March 2015 to August 2015) at diagnosis without any bias with 
respect to the GM and WM lesion load and were termed the Validation Set (VS). They were age 
and sex matched with the TS group. Each patient was then assigned to a low (VS-MSlow) or high 
(VS-MShigh) group based on whether their cortical lesion count was above or below the median 
number of 7 cortical lesions for the whole cohort (Table 2 and Fig 3).  
All the MS patients had a confirmed diagnosis of MS34 and underwent neurological 
evaluation, 3T-MRI and CSF examination.  
Twelve subjects with non-inflammatory neurological diseases (NIND), including 3 
cerebrovascular diseases, 3 degenerative disease, 2 periphery neuropathies, 2 headache/dizziness 
without any CNS abnormality, 2 ischemic white matter lesions, and 14 subjects with other 
inflammatory neurological diseases (OIND), including 3 immune-mediated encephalitis, 2 
neuromyelitis optica, 2 neurosarcoidosis, 2 leucoencephalopathies, 2 CNS paraneoplastic syndrome, 
2 CNS vascultis, 1 Behcet’s disease, were also recruited at the time of the diagnosis. They also 
underwent neurological evaluation, 3T-MRI and CSF examination.  
The local Ethic Committee approved the study. Informed consent was obtained from the 
patients.  
 
Post-mortem study 
Meningeal dissection and gene expression analysis 
Meningeal tissues closely adjacent to the areas of either subpial cortical demyelination or 
normal appearing GM, were dissected from snap frozen tissue blocks from 20 SPMS and 10 
controls (Table 1), as previously described5,15. To obtain a sufficient amount of RNA for gene 
expression analysis the RNA obtained from 3 tissue blocks per case was pooled. RNA extractions 
were performed using the RNeasy Lipid Tissue Midi Kit (Qiagen), following procedures previously 
optimized for use with human tissues35. The RNA concentration and quality were determined using 
a Nanodrop 2000 spectrophotometer and Agilent 2100 Bioanalyzer respectively.  
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Gene expression analysis of 84 human cytokines and chemokines was performed using a 
Qiagen RT Profile array (Human Cytokines & Chemokines RT2 Profiler PCR Array, cat. No. 
PAHS-150Z), following the manufacturer’s instructions, including the pre-amplification step (12 
cycles of 15s at 95C and 2 min at 60C). All samples were run in triplicate and the results analysed 
by two independent operators (R.M. and C.C.). 
 
Post-mortem CSF protein analysis 
The protein levels of 30 inflammatory cytokines and chemokines (V-PLEX Plus Human 
Cytokine 30-Plex kit) were determined in the post-mortem CSF obtained at autopsy from 20 SPMS 
(10 PM-MShigh and 10 PM-MSlow meningeal inflammation, Table 2) and 10 healthy controls 
using the MesoScale Discovery  electrochemiluminescence system (MSD; Meso Scale Diagnostics, 
Rockville, MD; Supplementary Table 1). The MSD detection system was used with the 
manufacturer’s protocol and provided a combination of high sensitivity with low background and a 
5 log order of magnitude dynamic range.  
 
Clinical study 
Patient CSF protein analysis 
CSF samples were obtained at least 2 months after the last relapse and within one week of 
the MRI, according to Consensus Guidelines for CSF and Blood Biobanking36. After centrifugation, 
the supernatant and the cell pellet were stored separately at -80 °C until use. Immunoglobulin-G 
(Ig-G) index and presence/absence of oligoclonal bands (OCB) for each MS patient is reported in 
Table 2. The CSF analysis was optimized and performed by two independent investigators (R.M. 
and S.R.), blinded with respect to the clinical and MRI features. The levels of neurofilament protein 
light chain (NF-L) in CSF were measured using the Human NF-light ELISA kit (MyBioSource, San 
Diego, CA, USA) according to the manufacturer’s instructions and the quantification was carried 
out on a VICTOR X3 2030 Multilabel Plate Reader (Perkin Elmer, Walluf, Germany). Intra-assay 
variability (coefficients of variation) of the samples was below 10%.  
The levels of 69 inflammatory mediators (Supplementary Table 2) were assessed using a 
combination of immune-assay multiplex techniques based on the Luminex technology (40- and 37-
Plex, Bio-Plex X200 System equipped with a magnetic workstation, BioRad, Hercules, CA, USA). 
All samples were run in duplicate in the same experiment and in two consecutive experiments, in 
order to verify the reproducibility and consistency of the results. The CSF level of each protein 
detected during the analysis was normalized to the total protein concentration of each CSF sample 
(measured by Bradford protocol). When comparing the two groups of 14 NIND and 12 OIND 
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controls, no differences were revealed in the presence and levels of the examined molecules 
Therefore, the two groups were included as a single control group. 
 
MRI Acquisition Protocol and analysis 
Three tesla MRI was performed on each patient at least 2 months from the last relapse, at the 
Radiology unit of the University Hospital of Verona (Borgo Trento). MRI sequences were acquired 
using a Philips Achieva 3T MR Scanner. The following image sets were acquired:  
a) 3D T1 weighted Turbo Field Echo (TFE) (Repetition Time (TR) / Echo Time (TE)= 
8.4/3.7ms, voxel size of 1x1x1 mm), Total acquisition time of 5:51 min;  
b) 3D Double Inversion Recovery (DIR) (TR/TE=5500/292ms, Inversion Times (TI) 
TI1/TI2=525ms/2530ms voxel size of 1x1x1mm), Turbo Spin Echo (TSE) read out with an 
optimal variable flip angle scheme, number of excitations 3, total acquisition time of 10:49 
min; and  
c) 3D Fluid Attenuated Inversion Recovery (FLAIR) (TR/TE=5500/292ms, TI=1650ms voxel 
size of 1x1x1mm), same TSE readout as the DIR sequence, number of excitations 1, total 
acquisition time of 5:44 min. 
 
MRI analysis 
A.  White matter lesion detection and lesion load assessment. 
A semiautomatic lesion segmentation technique, included in MIPAV (Medical Image 
Processing and Visualization. http://mipav.cit.nih.gov) software, was applied to FLAIR images, to 
identify and segment WM lesions, thus obtaining a T2 hyperintense WM lesion volume 
(T2WMLV) at baseline. 
B. Cortical lesion number and volume 
The number of cortical lesions was assessed on DIR images following the recent 
recommendations for cortical lesions scoring in patients with MS37. Such number included both 
intracortical and mixed (white matter/grey matter) lesions. In order of being as specific as possible, 
we have also calculated the number of intracortical lesions alone.  
The total CL volume and the volume of intracortical lesions were calculated using a 
semiautomatic thresholding technique based on a Fuzzy C-mean algorithm38 included in software 
developed at the National Institutes of Health, Medical Images Processing, Analysis and 
Visualization (http://mipav.cit.nih.gov). 
 
C.  Cortical thickness evaluation.  
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The estimation of the cortical thickness was performed using the 3D T1 TFE sequence and 
the automated, volume-based Advanced Normalization Tools (ANTs)39 and, in particular, the ANTs 
Cortical Thickness pipeline39. Particular attention was paid to exclude WM lesions that could 
hamper the estimation of atrophy even with a low WM lesion load39 . Therefore, the segmentation 
of T2 hyperintensity obtained in step A was used as a mask for the lesion filling of 3D T1. The co-
registration of T1 and FLAIR images was operated with a rigid body transformation with ANTs. 
The mask was then moved onto the 3D T1. The lesion filling was operated with the lesion filling 
routine included in Lesion Segmentation Tool40. The 3D T1 after lesion filling was then visually 
evaluated and manually corrected (the lesion filling step was run a second time with the new 
manually corrected lesion mask). 
 
Statistical analysis  
For the neuropathological and clinical study, differences among groups were assessed 
through analysis of variance (ANOVA). Age was used as a correction covariate and post hoc Tukey 
HSD procedure to account for multiple comparisons. Rank-based non-parametric tests (Kruskal-
Wallis and Wilcoxon) were used when the data did not follow a normal distribution (Shapiro test). 
The Pearson Chi Square test was applied to test the difference between groups in terms of 
male/female ratio, patients with and without IgG oligoclonal bands and patients with 
polysymptomatic onset. False discovery rate (FDR) with significance level of 0.05 was adopted to 
correct for the multiple testing problem in the analysis of the CSF protein expression.  
In order to evaluate the specificity and sensitivity of each molecule in predicting high or low 
cortical damage, different thresholds for each molecule were used to classify patients as MSlow or 
as MShigh and for each identified threshold the number of true positives and false positives were 
recorded in a ROC curve (Supplementary Table 3). 
For the multivariate analysis, we utilised as independent variables those cytokines that were 
consistently raised across both post-mortem and in vivo groups and those that were raised in both 
patient groups and neurofilament protein light levels. Models were run using both cortical lesion 
number and cortical volume as an outcome using the total population. 
 
 
RESULTS 
 
Study cohorts and subgroup classification - post mortem cohort 
Post-mortem SPMS cases were stratified according to the degree of meningeal 
inflammation: the PM-MSlow group (Table 1; Fig 1 A, C, E), with a low density of diffuse 
meningeal inflammation, and the PM-MShigh group, characterised by a significantly increased 
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degree of meningeal inflammatory infiltration (6.5 fold change, p<0.0001; Fig 1A, D, F, G-I). In 
particular, a high frequency of immune cell aggregates rich in CD20+ B cells and CD3+ T cells 
(Fig 1G-I) was present in the subarachnoid space in the PM-MShigh group (Table 1; Fig1 F-I). The 
PM-MShigh group was also characterized by a significant increase (2.9-fold, p<0.0001) in the 
percentage of GM demyelination (Fig 1B; mean=70.03%; range= 56-82%) compared to the PM-
MSlow group (Fig 1B; mean=28.7%; range=6-51%,). In addition, the PM-MShigh group had a 
significantly earlier age at use of a wheelchair and at death (36.6±7.39, 47.1±7.2) when compared 
to the PM-MSlow group (46±6.43, p=0.012; 56.4±6.13, p=0.015), but no significant difference in 
disease duration. 
 
Increased meningeal inflammation in the post-mortem MS brain is associated with elevated 
gene expression of pro-inflammatory mediators  
Significantly elevated gene expression for the pro-inflammatory molecules TNF, IFNγ, IL2, 
IL22, CXCL9, CXCL10, CXCL13, CXCL20 and CCL22 was found in the meninges of the PM-
MShigh group compared to controls, whereas IL9, IL17 and IL22 (Fig 2A) gene expression was up-
regulated in the PM-MSlow group compared to controls. A significant increase in the expression of 
the CXCL9, CXCL10, CXCL13 and TNF (Fig 2A) genes was found in the meninges of the PM-
MShigh group compared to the PM-MSlow group, whereas IL17A (Fig 2A) gene expression was 
elevated in the PM-MSlow compared to the PM-MShigh group. 
Significantly higher protein levels of TNF, LTα, IFNγ, CXCL10, CXCL13, CCL17, 
CCL22, IL2, IL10, IL12p40 and IL16 were found in the CSF of PM-MShigh compared to controls 
and only IL-4 was increased in the CSF of PM-MSlow compared to controls (Fig 2B). When the 
PM-MShigh cases were compared to the PM-MSlow cases, there was a significant increase in the 
levels of TNF, LTα, CXCL13, CCL22 and IL12p40 (Fig 2B). In contrast, only IL4 protein was 
increased in the CSF of PM-MSlow compared with the control group (Fig 2B). There was no 
significant difference in the CSF protein levels of IL17 between the groups (not shown).  
 
Study populations and subgroup classification – in vivo patient population 
The demographics and clinical features of the TS population are described in Table 2. 
Fifteen patients were classified as TS-MSlow and 20 patients as TS-MShigh on the basis of the 
number of total cortical lesions (see methods). Compared to the TS-MSlow group (Fig 3A), TS-
MShigh patients (Fig 3B) were characterized by higher cortical lesion load (16.8 ± 6.4 vs 0.3 ± 0.5, 
p<0.0001) (Table 2), higher EDSS (2 vs 1.5, p=0.017), higher T2WMLV (5.6±1.6 vs 4.7±1.6, 
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p=0.031) and lower mean cortical thickness over the entire brain (2.53 ± 0.34 vs 2.72 ± 0.41 , 
p=0.032) (Table 2).  
When the number of merely intracortical lesions (including cortical lesion type II and III) was used 
to classify the patients such classification did not change: higher cortical lesion load was indeed 
found in T-MShigh compared to T-MSlow (7.55 ± 3.6 vs 0.2 ± 0.4, p<0.001). 
 
Higher cortical lesion load at diagnosis is associated with increased CSF neurofilament light 
chain protein levels 
Significantly increased CSF NF-L protein was found in the TS-MSlow (fold change=1.9, 
p=0.003) and TS-MShigh (fold change=3.97, p<0.001) patients compared to controls (Fig 3C). CSF 
NF-L was also increased in the TS-MShigh group compared to the TS-MSlow group (fold 
change=2.3, p<0.001) (Fig 3C). Furthermore, we found a significant correlation between the CSF 
protein level of NF-L and both the volume (r=0.406; p=0.015) and the number of cortical lesions 
(r=0.421; p=0.011), but not with T2-WMLV (r=-0.046; p=0.716). 
 
Higher cortical lesion load at MS diagnosis is associated with increased pro-inflammatory 
CSF cytokine and chemokine expression 
The protein levels of TNF, sTNFR1, IFNγ, CXCL12, CXCL13, IL6, IL8, IL-10, BAFF, 
APRIL, LIGHT, TWEAK, MMP-2, Pentraxin3 and sCD163 were increased in the CSF of the TS-
MShigh group compared to both control and TS-MSlow groups (FDR < 0.05) (Fig 4). Only the 
protein levels of IFN-α2, IFN-λ2 and CCL25 were significantly increased in the TS-MSlow group 
compared to both control and TS-MShigh groups. To address the specificity and sensitivity of 
individual molecules as biomarkers in classifying patients into MSlow and MShigh, we performed 
the ROC curve analysis (Supplementary Table 3): all these 18 molecules showed a very good 
classification performance (AUC ≥ 0.80).  
 
Validation of biomarker candidates using an independent cohort of MS patients 
The association between CSF NF-L and cortical lesion load found in the TS was validated in 
the independent VS cohort. An increased NF-L protein expression was also found in VS-MSlow 
(fold change=2.4, p=0,049) and VS-MShigh patients (fold change=5.4, p<0.0001) compared to 
controls, and in VS-MShigh compared to VS-MSlow (fold change=2.2, p=0.0005) (Fig 3C).  
All molecules found to be differentially expressed between TS-MShigh and TS-MSlow 
were also differentially expressed between VS-MSlow and VS-MShigh groups in our validation 
analysis, with the exception of IL6 and TWEAK (Fig 4). Specificity, sensitivity and accuracy in 
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classifying cases with a high cortical lesion load and intrathecal inflammation was obtained by 
ROC analysis of these 18 molecules: except for TWEAK and IL-6, all the other molecules showed 
a good accuracy in classifying cases in this way (AUC ≥ 0.70, Supplementary Table 3).  
In agreement with the training set results, the classification of the validation set into VS-
MSlow and VS-MShigh did not change when the intracortical lesions alone when used to classify 
the patients. 
 
Comparison of the post-mortem and patient studies.  
Among all the molecules analysed from the post-mortem and clinical cohorts, TNF, IFNγ, 
CXCL13 and IL10 were commonly increased in the CSF of PM-MShigh compared to PM-MSlow, 
TS-MShigh compared to TS-MSlow and in VS-MShigh compared to VS-MSlow groups (Fig 5A). 
In addition, TNF, IFNγ and CXCL13 gene expression were correspondingly found upregulated in 
the meninges of the PM-MShigh compared to PM-MSlow group (Fig 5). Together these three 
molecules show a good association (specificity 80%, sensitivity 100%) with the outcome VS-
MShigh vs VS-MSlow. Moreover, a linear multivariate model was developed (Table 3) containing 
as independent variables IFNγ, TNF, CXCL12, CXCL13, IL6, IL10 and LIGHT, which 
demonstrates that these variables explain 89% of the variance in cortical lesion volume (n=39, R2 
0.8856, p<0.0001) and 87% of the variance in cortical lesion number (n=39, R2 0.876, p<0.0001). 
There were no significant variables that could predict T2WMLV (data not shown). Furthermore, we 
found that the three cytokines that were elevated in the post-mortem meninges and CSF and in both 
patient groups, namely TNF, IFNγ and CXCL13 explained in turn 88% (0.7824/0.8856) of the 
variance explained by the 7 cytokine model for cortical lesion number (Fig 6A) and 86% 
(0.7511/0.8752) of the variance for cortical lesion volume (Fig 6B).  
 
 
DISCUSSION 
 
We have identified an intrathecal (meninges and CSF) inflammation profile in a post-
mortem MS cohort that is defined by high levels of GM demyelination and meningeal 
inflammation. The molecular pattern of increased CSF pro-inflammatory cytokines and chemokines 
(TNF, LTα, IFNγ, IL2, IL10, IL12p40, IL16, CXCL10, CXCL13, CXCL20, CCL17 and CCL22) 
was associated with increased meningeal inflammation and GM demyelination and, in addition, 
early disability onset and age at death. The finding of increased intrathecal levels of molecules 
associated with B cell recruitment and activity (CXCL13, CXCL10, IL6, IL10, TNF and LTα), 
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together with their increased gene expression, in the subgroup of post-mortem MS patients with 
high meningeal inflammation and cortical GM demyelination, strongly suggests a link between the 
degree of the compartmentalized meningeal immune response and both the underlying cortical 
pathology and a more rapid disease evolution. The lack of tight junctions in cells lining the pial 
membrane, damage to the glia limitans caused by the inflammation5 and a degree of continuity 
between the subarachnoid and perivenular spaces would allow proteins derived from circulating 
CSF to easily reach the underlying GM41. Due to the similarity between the changes in mRNA 
levels in the meninges and protein levels in the CSF, we suggest that immune cells in the 
subarachnoid space, whether diffuse or focally organized, release inflammatory/cytotoxic mediators 
into the CSF, creating a intracerebral milieu that sustains chronic compartmentalized inflammation 
and, at the same time, directly mediates and/or exacerbates cortical pathology and disease 
progression41. It was not possible to include in our study post-mortem CSF samples from cases of 
non-MS CNS inflammatory conditions, so we cannot say at this stage that the clear association 
between the particular combination of cytokines and chemokines and the underlying cortical 
pathology is specific to MS.    
In order to determine whether the post-mortem CSF profiles are present at earlier stages in 
the disease process, we analysed the intrathecal immune profile associated with increased cortical 
pathology at the time of diagnosis of two independent groups of MS patients. The groups of MS 
patients with increased GM damage on MRI showed a remarkably similar, but not identical, CSF 
profile when compared to the post mortem samples with increased GM demyelination, even at this 
early stage of disease. This is in agreement with the observation of substantial meningeal infiltrates 
and subpial demyelination in cortical biopsies of patients at the early stages of disease11. Even the 
protein levels in vivo were quantitatively similar to those observed in the post-mortem samples. In 
particular, a combination of pro-inflammatory cytokines (TNF, IFNγ, IL6) and molecules involved 
in lymphoid-neogenesis (CXCL12, CXCL13, TNF) and B-cell and plasma cell/blast activity (IL6, 
IL10, TNF, BAFF, APRIL, LIGHT, TWEAK) defined those subjects with the most extensive GM 
demyelination. The further analysis of CSF from an independent unbiased cohort of MS patients 
with an heterogeneous degree of disease severity, who were consecutively enrolled in the neurology 
clinic at the time of diagnosis, identified an almost identical cytokine/chemokine profile, thus 
validating and increasing confidence in our findings. The elevated CSF expression of major 
inflammatory molecules, such as TNF, IFNγ, BAFF, IL6 and IL8, suggests the presence of an 
elevated involvement of multiple immune cell populations, including T lymphocytes and 
monocytes, indicating an increased inflammatory activity that probably characterizes patients with 
increased cortical pathology and a more progressive clinical disease. In addition, the different 
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immune populations contributing to the intracerebral inflammatory activity might also have an 
important role in the activation and regulation of the B-cell and plasma blast functions.  
In contrast, although less well defined, a different inflammatory profile associated with 
innate and myeloid immunity (type I and III IFNs) and Th2 regulatory molecules (CCL25), was 
observed in the CSF of MS patients with low GM lesion number and volume. This suggests that the 
balance of inflammatory mechanisms in this patient group is altered towards the downregulation of 
pro-inflammatory pathways. In this context, the increase in gene expression for IL17 in the post-
mortem meninges of MS cases with only low levels of inflammation and demyelination was 
somewhat surprising given its role in promoting meningeal inflammation in mice51 and points 
towards a possible immunoregulatory role in this compartment in progressive MS . However, no 
significant difference was seen in the levels of IL17 protein in the post-mortem CSF and it was not 
included in the multiplex analysis of the patients samples. Further investigations are thus required to 
understand the role of IL17 in progressive disease.    
It is intriguing that such a CSF profile includes high levels of molecules linked to B cell 
recruitment and maintenance in the CNS (CXCL13 and CXCL12) as well as mediators related to B 
cell immune functions (IL6, IL10, TNF, BAFF, APRIL, TWEAK) at this early stage of the disease 
evolution. This supports a key role for a compartmentalized B cell and plasma cell/blast response in 
the pathogenesis of GM damage at least in a subgroup of patients from an early stage14,42,43. Such 
data reinforces the idea that the immune response is compartmentalised and may help to explain 
why most of the immunomodulatory drugs are ineffective in progressive MS44,45 as they do not 
efficiently access this compartment. Our observations are also in line with previous 
studies6,17,29,42,46,47 and confirm the key role of a compartmentalized adaptive immune response that 
specifically mediates and exacerbates the pathology of the adjacent cerebral cortex in MS. The 
finding of specific individual CSF/MRI profiles linked to the degree of meningeal inflammation and 
cortical lesion load at the time of the diagnosis suggests that a specific differential involvement of 
intrathecal inflammatory responses, possibly compartmentalized in ectopic lymphoid-like 
structures, and of GM demyelination might be linked to long term disease evolution.  
To confirm that the patient group with a higher cortical lesion load on MRI (TS-MShigh) 
are characterized by a more severe GM damage we have also evaluated the global cortical thickness 
(a general proxy of GM atrophy) and the levels of NF-L in the CSF. Both these parameters clearly, 
suggest that the inflammatory and neurodegenerative processes within the GM are significantly 
more aggressive in patients with a higher cortical lesion load, as previously suggested by a number 
of imaging studies9 . They also confirm previous neuropathological findings of increased axonal and 
neuronal loss in subpial GM lesions of MS patients with increased levels of meningeal 
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inflammation and more rapid disease progression5,6,14,18 suggesting that intrathecal inflammatory 
milieau may be one of the key determinant of the rate of cortical neurodegeneration in MS.  
The combined post-mortem and patient results suggest that cortical damage in MS is 
associated with a specific inflammatory intrathecal profile that is already detectable at disease 
onset, persists throughout the entire disease course, and can be still detected at the final stage of the 
disease in the post-mortem brain, although further longitudinal studies are necessary to substantiate 
this idea. Moreover, these data point out the crucial value of the CSF analysis, suggesting that it 
might be possible to identify MS patients at high risk of severe GM damage already at the point of 
diagnosis by a specific combined CSF and MRI profile. Finally, the association of both severe GM 
damage and meningeal inflammation with a more rapidly progressing disease, as observed by 
several imaging8 and post-mortem studies 6,11,14,17, also confirms the possible prognostic value of 
such data and the possibility to stratify patients for more appropriate treatment options already at 
diagnosis. In particular, the panel of molecules commonly identified in both the neuropathological 
and clinical arms of the study (CXCL13, IL10, TNF and IFNγ) might represent a useful prognostic 
signature of cortical damage and meningeal inflammation, linked to a more rapid and severe disease 
progression.  
The fact that the classification into two MS subgroups with substantially different cortical 
lesion load at diagnosis was also confirmed when only intracortical lesions alone where used to 
classify the patients. This strongly supports the existence of a “cortical variant” of multiple sclerosis 
in which the cerebral cortex is predominantly or exclusively involved 48 . 
Although four different experiments have been conducted to increase the reliability of our 
data, this study is not without limitations. We see the low sensitivity of MRI methodologies in 
detecting all cortical lesions in vivo to be a limitation, although comparative neuropathological and 
in vivo studies have suggested that the load of detectable MRI cortical lesions is well correlated 
with the total number of cortical lesions observed by neuropathological assessments, including the 
most numerous sub-pial type III cortical lesions 49,50. Nevertheless, to overcome this limitation and 
to identify patients with a more severe cortical pathology, we also included in our analysis a reliable 
evaluation of cortical thickness and of CSF NF-L as additional markers of GM damage. Moreover, 
we have analysed post-mortem tissues applying the same criteria (cases are differentiated according 
to cortical lesion load) used for the MS patients. As the examined post-mortem MS population was 
made up of SPMS cases, the level of cortical demyelination is of course substantially more severe 
than the one detected in RRMS patients at diagnosis by 3T-MRI methodology. However, such a 
combined analysis used in this study still suggests that it may be possible to stratify MS patients 
according to the GM lesion load and inflammatory profile at any disease stage.  
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A further limitation of this study may be the stringent biostatistical analyses performed, 
which might have underestimated the number of significant biomarkers. Extending this study to a 
larger MS population could help to identify a more complex and complete panel of CSF biomarkers 
associated with cortical damage and intrathecal inflammation. Finally, the lack of a clinical follow 
up at this stage has necessitated the use of several surrogate markers of disease severity to indicate 
the development of an early and severe GM damage. Therefore, longitudinal studies are required to 
confirm, in vivo, that the CSF profile associated with the severe GM damage can be used as a 
prognostic marker of disease evolution.  
In conclusion, our analysis has identified a set of inflammatory mediators in patient CSF 
captured at diagnosis, which reflects the state of meningeal inflammation and the extent of cortical 
damage, which is comparable to that seen post-mortem in neuropathologically characterised MS. 
The similarity of such a CSF profile with that observed at death in more rapidly progressive MS 
cases, strongly reinforces a potential key role of CSF analysis at disease onset and indicates its 
possible utility as a prognostic marker for MS course from the early phase of the disease. Since 
modern advanced imaging techniques are not yet able to specifically identify and quantify 
meningeal inflammation16 and subpial demyelination, we propose the combined CSF and MRI 
profiling of the MS patients at diagnosis will be an appropriate in-vivo surrogate of meningeal and 
intrathecal inflammation and might help to define other different specific MS phenotypes related to 
the characteristic heterogeneity of the disease and subsequently to select the most appropriate 
treatment.  
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Legends 
 
Figure 1 
Neuropathological assessment showing the association between meningeal inflammation and 
grey matter demyelination. In contrast to the PM-MSlow group (A-C, E), the PM-MShigh group 
was characterized by high degree of meningeal inflammation (A, F-I), particularly enriched in 
CD20+ B cells and CD3+ T cells (G-I), and high levels of cortical demyelination (B, D, F). A: 
Quantifying the number of cells per meningeal inflammatory infiltrates in PM-MSlow group (green 
bars; mean=10.42; SEM=2.48; range= 7-32) compared with the PM-MShigh (red bars; 
mean=68.83; SEM=7.8; range= 43-167) significant higher meningeal inflammation (fold change: 
6.5; p<0.0001) was detected in PM-MShigh compared to the PM-MSlow group. B: Quantification 
of cortical GM demyelination in PM-MSlow group (green bars; median=24.5% + SEM=2.016; 
range=14-51%) compared with the PM-MShigh group (red bars; median=71% + SEM=1.12; 
range= 57-82%) revealed significant increased (fold change: 2.9; p<0.0001) GM demyelination was 
found in PM-MShigh compared to the PM-MSlow group. (B; immunostaining for myelin 
oligodendrocyte glycoprotein in ; MOG) and meningeal cellular infiltrates (D). Scale bars = (C, D) 
5 mm; (E, F) 2.5 mm; (G-I) 20 µm. 
 
Figure 2 
Analysis of the changes in levels of inflammatory gene transcripts and proteins in post-
mortem meninges and CSF of MS and control cases. Analysis of the presence and levels of 
inflammatory gene transcripts (A) and protein (B) in the post-mortem meninges (A) and CSF (B) 
respectively, in 10 controls (yellow bars), 10 PM-MSlow (green bars) and 10 PM-MShigh cases 
(red bars). Significantly increased expression of gene transcripts (A) and correspondent proteins (B) 
for CXCL13, TNF, IFNγ, CXCL10, IL2 and CCL22 were found in PM-MShigh cases compared to 
controls. CXCL13, TNF and CXCL10 gene expression was increased in PM-MShigh compared to 
PM-MSlow (A), whilst CXCL13, TNF and CCL22 protein expression was increased in the CSF of 
PM-MShigh compared to PM-MSlow groups (B).  
Significantly elevated gene expression for the pro-inflammatory molecules TNF, IFNγ, IL2, 
IL22, CXCL9, CXCL10, CXCL13, CXCL20 and CCL22 was found in the meninges of the PM-
MShigh group compared to controls; IL9 and IL17 gene expression was up-regulated in the PM-
MSlow group compared to controls; CXCL9, CXCL10, CXCL13 and TNF genes expression was 
up-regulated in the meninges of the PM-MShigh group compared to the PM-MSlow group; finally, 
IL17A gene expression was elevated in the PM-MSlow compared to the PM-MShigh group (A). 
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Significantly higher protein levels of all the reported molecules in B, except IL-4, were 
found in the CSF of PM-MShigh compared to controls; only IL-4 was increased in the CSF of PM-
MSlow compared to controls (B). When the PM-MShigh cases were compared to the PM-MSlow 
cases, there was a significant increase in the levels of TNF, LTα, CXCL13, CCL22 and IL12p40 
(B). In contrast, only IL4 protein was increased in the CSF of PM-MSlow compared with the 
control group (B) p values for each statistically significant comparison have been reported 
(*=p<0.05; **=p<0.01; ***=p<0.001). 
 
Figure 3 
Imaging cortical pathology in the MS study cohort. Patients were grouped based on the presence 
of at least 10 CLs (TS-MShigh) or less that 2 CLs (TS-MSlow). Illustration of MRI profile 
representative of the T-MSlow group (A) and the T-MShigh subjects (B). 3D Double Inversion 
Recovery MRI acquisitions are reported in three views: axial, coronal and sagittal, respectively. 
CLs (red arrows) and WM lesions (green arrows) are highlighted. Protein expression of NF-L in the 
diagnostic CSF (C) taken from 26 controls (yellow bar), 15 T-MSlow (green bar), 20 T-MShigh 
(red bar), 19 V-MSlow (green bar with texture) and 19 V-MShigh (red bar with texture) patients. 
Statistical analysis of the data was performed using the non parametric Mann-Whitney test. p values 
for each statistically significant comparison are reported (*=p<0.05; **=p<0.01; ***=p<0.001). 
 
Figure 4 
CSF protein analysis in MS and control cohorts. Protein levels of the 18 CSF biomarkers found 
differentially expressed in the CSF of 26 controls (ctrls; yellow bar), 15 TS-MSlow (green bar), 20 
TS-MShigh (red bar), 19 VS-MSlow (green bar with texture) and 19 VS-MShigh (red bar with 
texture) patients. The levels of CXCL13, CXCL12, CCL25, TNF, sTNFR1, IFNγ, IFN-α2, IFN-λ2, 
IL6, IL8, IL-10, BAFF, APRIL, LIGHT, TWEAK, GM-CSF, MMP-2, Pentraxin3 and sCD163 
were significantly increased in the CSF of the TS-MShigh and VS-MShigh groups compared to 
controls (FDR < 0.05). Only the levels of IFN-α2, IFN-λ2, CCL25 were significantly elevated in 
the MSlow groups compared to both controls and MShigh groups. Significant increases in 
CXCL12, CXCL13, IFNγ, TNF, TNFR1, APRIL, LIGHT and BAFF were also observed in the CSF 
of TS-MShigh and VS-MShigh compare to TS-MSlow and VS-MSlow groups respectively. 
Statistical analysis of the data was performed using the non parametric Mann-Whitney test. p values 
for each statistically significant comparison have been reported (*=p<0.05; **=p<0.01; 
***=p<0.001). 
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Figure 5 
Comparison of the post-mortem and in-vivo patient studies.  
All differentially expressed inflammatory molecules identified from the post-mortem (meningeal 
gene expression and CSF protein expression) and clinical studies (CSF protein expression in the 
training and validation MS cohorts) are shown (A) to highlight the immune mediators that best 
reflect a state of increased cortical pathology at both diagnosis and post-mortem. In both the studies, 
the molecules overexpressed in MSlow groups are shown in green, while the molecules 
overexpressed in MShigh groups are shown in red. Molecules overexpressed only in the post-
mortem or in the in-vivo group of patients are represented in yellow. TNF, IFNγ, CXCL13 and 
IL10 (black arrows) were found overexpressed in the CSF of both PM-MShigh (compared to PM-
MSlow) and in TS-MShigh and in VS-MShigh (compared to TS-MSlow and VS-MSlow). In 
addition, the TNF, IFNγ and CXCL13 gene expression was found correspondingly upregulated in 
the meninges of PM-MShigh compared to PM-MSlow.  
 
Figure 6 
Predicting model of cortical damage.  
Influence of each cytokine on the chance of cortical lesions (A) and volume (B) in the in-vivo 
examined MS populations: TNF, IFNγ, CXCL13 might explain 88% of cortical lesion number (A) 
and 85% of cortical lesion volume (B). 
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Table 1: Demographic and clinical characteristics of the post-mortem cases. 
 
Abbreviations= DisDur: disease duration; AgeWC: age at wheelchair use (EDSS 7); PM interval: post-mortem interval; 
CSF: cerebrospinal fluid; N.A.: not available; N.W.: not wheelchair bound; N.U.: not used as not presenting with 
neuropathological features of interest. 
 
Cases Sex 
Age at 
Death Cause of death 
PM interval 
(hrs) 
C5 F 95 Bronchopneumonia 9 CSF and meningeal analysis 
C7 F 85 Oesophageal cancer 9 CSF and meningeal analysis 
C8 F 93 Bronchopneumonia,  9 Meningeal analysis only 
C25 M 35 Tongue carcinoma 22 Meningeal analysis only 
C28 F 60 Ovarian cancer 13 Meningeal analysis only 
C30 M 75 Bronchopneumonia 17 CSF and meningeal analysis 
C32 M 88 Prostate cancer 12 CSF and meningeal analysis 
C36 M 68 Heart failure 30 CSF and meningeal analysis 
C45 M 77 Myocardial degeneration  22 Meningeal analysis only 
C50 M 32 Haeman-giopericytoma  6 CSF and meningeal analysis 
C54 M 66 Pancreatic Cancer 16 CSF and meningeal analysis 
PDC22 M 75 Lung carcinoma 10 CSF analysis only 
PDC32 F 91 Colon cancer 12 CSF analysis only 
PDC36 F 57 Breast cancer 15 Used for CSF 
      
MS104 M 53 Multiple sclerosis 12 pm-MS1 (meninges + CSF) 
MS296 M 59 Multiple sclerosis 22 pm-MS1 (meninges + CSF) 
MS301 F 62 Septicaemia 16 pm-MS1 (meninges only) 
MS304 M 52 Pulmonary embolism 13 pm-MS1 (meninges + CSF) 
MS311 F 45 Pneumonia 22 pm-MS1 (meninges only) 
MS318 F 59 Multiple sclerosis 13 pm-MS1 (meninges + CSF) 
MS326 M 62 Multiple sclerosis 24 pm-MS1 (meninges only) 
MS347 M 50 Pancreatic carcinoma 13 pm-MS1 (meninges + CSF) 
MS364 F 56 Bronchopneumonia 14 pm-MS1(CSF only) 
MS376 F 58 Multiple sclerosis 19 pm-MS1 (meninges only) 
MS422 M 58 Bronchopneumonia 25 pm-MS1 (CSF only)  
MS444 M 49 Renal failure 18 pm-MS1(CSF only) 
MS461 M 43 Bronchopneumonia 13 pm-MS1(CSF only) 
MS485 F 57 Bronchopneumonia 24 pm-MS1(CSF only) 
MS491 F 64 Anaphylactic reaction 9 pm-MS1 (meninges only) 
      
MS402 M 46 Multiple sclerosis 12 pm-MS2 (meninges + CSF) 
MS407 F 44 Septicaemia 22 pm-MS2 (meninges + CSF) 
MS408 M 39 Pneumonia 21 pm-MS2 (meninges + CSF) 
MS423 F 54 Pneumonia 11 pm-MS2 (meninges + CSF) 
MS438 F 53 Multiple sclerosis 17 pm-MS2 (meninges + CSF) 
MS473 F 40 Bronchopneumonia 9 pm-MS2 (meninges + CSF) 
MS497 F 60 Aspiration pneumonia 45 pm-MS2 (meninges + CSF) 
MS510 F 38 Pneumonia 19 pm-MS2(meninges only) 
MS513 M 51 Multiple sclerosis 17 pm-MS2 (meninges + CSF) 
MS517 F 48 Chest sepsis 12 pm-MS2 (CSF only) 
MS527 M 46 Pneumonia 10 pm-MS2 (meninges only) 
MS528 F 45 Multiple sclerosis 17 pm-MS2 (CSF only) 
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Table 2. Demographics and disease characteristics of the MS subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: EDSS: Expanded Disability Status Scale; OCB: oligoclonal bands; IgG index: immunoglobulin-G 
index; PM: post-mortem; GM: grey matter; CL: cortical lesion; CTh: cortical thickness; T2WMLV: T2 white matter 
lesion volume; N.A.: not available. 
 
Group Post-mortem (PM) Patient Test set (TS) Patient Validation set (VS) 
MS damage Low (15) High (12) Low (15) High (20) Low (19) High (19) 
Age studied 
(mean±SD) 
 55±6.34  45.8±5.42  38.4±11.3   33.2±11.1   35.0±11.1   32.5±10.6  
Gender (f:m)  7:8  7:5  10:5   15:5  11:8   12:7 
Disease duration 
(mean±SD years) 
 24.0±8.5  21.1±6.1  2.1±2.4   3.3±2.0  2.1±2.3   3.2±2.4 
EDSS at 
recruitment 
(range) 
  
 1.5 (1.0-3.5)  2.0 (1.0-4.0)  1.0 (1.0-3.5)  2.0 (1.5-4.5) 
Mono/poly 
symptomatic 
onset/not 
available 
4/4/7 6/1/4 
15/0/0 15/5/0 17/2/0 16/3/0 
OCBs 
Positive/negative
/not available 
4/0/11 3/0/9  12/3/0  18/2/0  13/6/0  16/3/0 
IgG index N.A. N.A. 0.61±0.15 0.78±0.25 0.82±0.42 1.08±0.49 
PM GM damage 
assessment 
(mean±SD) 
28.43% ± 
11.04 
70.03% ± 
6.34 
- - - - 
CLs volume 
(mm3- range) 
 
- - 
49 ± 74  
(0-188) 
1713 ± 663  
(877-2678) 
187 ± 204  
(0-575) 
1579 ± 774  
(791-3910) 
CLs number 
(mean±SD) 
- - 
0.3 ± 0.5  
(0-1) 
16.8 ± 6.4  
(10-29) 
1.9 ± 2.0  
(0-5) 
11.4 ± 2.5  
(8-16) 
CTh (mm; range) - - 
2.72 ± 0.41  
(2.45-3.15) 
2.53 ± 0.34  
(2.31-2.99) 
2.83 ± 0.25  
(2.54-3.12) 
2.62 ± 0.31  
(2.34-3.01) 
T2WMLV (cm3; 
range) 
 -  - 4.7±1.6  
(1.4-7.2) 
5.6±1.6  
(3.1-8.4) 
5.2 ±1.9  
(2.5-8.4) 
6.3±1.8  
(3.4-9.2) 
Page 27 of 39
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
Table 3. Models predicting the cortical lesion volume and number using 8 cytokines. 
 
Models predicting the cortical lesion volume and number using 8 cytokines which demonstrates that these 
molecules may explain 89% of the variance in predicting CL volume (n=39, R
2
 0.8856, p<5.057e-16) and 
87% of the variance in CL number (n=39, R
2
 0.8752, p<2.689e-15). 
Variable estimate (95%CI 
lower, upper, p value) 
Model 
  Cortical lesion volume (R2 0.8856) Cortical lesion number (R2 0.8752) 
IFNγ 
  
26.4769 (9.5229, 43.4308, p=0.003) 0.3437 (0.1840,  0.5034, p=9.38e-05) 
TNF 4.9407 (0.6130, 9.2684, p=0.0263) 0.0362594 (-0.0045,  0.0770, p=0.0797) 
CXCL13 12.900 (6.7815, 19.0187, p=0.00012) 0.1334 (0.0758, 0.1911, p=3.39e
-05) 
CXCL12 0.2720 (0.1071, 0.4369, p=0.00187) 0.0024 (0.0009, 0.0040, p=0.00324) 
IL6 42.7753 (18.2392,  67.3114, p=0.0011) 0.4087 (0.1776, 0.6398, p=0.00095) 
IL10 -52.2696 (-92.1966, -12.3425, p=0.0116) -0.3869 (-0.7629, -0.0108, p=0.044) 
LIGHT 0.2677 (0.1249, 0.4105, p=0.0005) 0.0025 (0.0011, 0.0039, p=0.00053) 
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Figure 1  
Neuropathological assessment showing the association between meningeal inflammation and grey matter 
demyelination. In contrast to the PM-MSlow group (A-C, E), the PM-MShigh group was characterized by high 
degree of meningeal inflammation (A, F-I), particularly enriched in CD20+ B cells and CD3+ T cells (G-I), 
and high levels of cortical demyelination (B, D, F). A: Quantifying the number of cells per meningeal 
inflammatory infiltrates in PM-MSlow group (green bars; mean=10.42; SEM=2.48; range= 7-32) compared 
with the PM-MShigh (red bars; mean=68.83; SEM=7.8; range= 43-167) significant higher meningeal 
inflammation (fold change: 6.5; p<0.0001) was detected in PM-MShigh compared to the PM-MSlow group. 
B: Quantification of cortical GM demyelination in PM-MSlow group (green bars; median=24.5% + 
SEM=2.016; range=14-51%) compared with the PM-MShigh group (red bars; median=71% + SEM=1.12; 
range= 57-82%) revealed significant increased (fold change: 2.9; p<0.0001) GM demyelination was found 
in PM-MShigh compared to the PM-MSlow group. (B; immunostaining for myelin oligodendrocyte 
glycoprotein in ; MOG) and meningeal cellular infiltrates (D). Scale bars = (C, D) 5 mm; (E, F) 2.5 mm; (G-
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I) 20 µm.  
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Figure 2  
Analysis of the changes in levels of inflammatory gene transcripts and proteins in post-mortem meninges 
and CSF of MS and control cases. Analysis of the presence and levels of inflammatory gene transcripts (A) 
and protein (B) in the post-mortem meninges (A) and CSF (B) respectively, in 10 controls (yellow bars), 10 
PM-MSlow (green bars) and 10 PM-MShigh cases (red bars). Significantly increased expression of gene 
transcripts (A) and correspondent proteins (B) for CXCL13, TNF, IFNγ, CXCL10, IL2 and CCL22 were found 
in PM-MShigh cases compared to controls. CXCL13, TNF and CXCL10 gene expression was increased in PM-
MShigh compared to PM-MSlow (A), whilst CXCL13, TNF and CCL22 protein expression was increased in the 
CSF of PM-MShigh compared to PM-MSlow groups (B).  
Significantly elevated gene expression for the pro-inflammatory molecules TNF, IFNγ, IL2, IL22, CXCL9, 
CXCL10, CXCL13, CXCL20 and CCL22 was found in the meninges of the PM-MShigh group compared to 
controls; IL9 and IL17 gene expression was up-regulated in the PM-MSlow group compared to controls; 
CXCL9, CXCL10, CXCL13 and TNF genes expression was up-regulated in the meninges of the PM-MShigh 
group compared to the PM-MSlow group; finally, IL17A gene expression was elevated in the PM-MSlow 
compared to the PM-MShigh group (A).  
Significantly higher protein levels of all the reported molecules in B, except IL-4, were found in the CSF of 
PM-MShigh compared to controls; only IL-4 was increased in the CSF of PM-MSlow compared to controls (B). 
When the PM-MShigh cases were compared to the PM-MSlow cases, there was a significant increase in the 
levels of TNF, LTα, CXCL13, CCL22 and IL12p40 (B). In contrast, only IL4 protein was increased in the CSF 
of PM-MSlow compared with the control group (B) p values for each statistically significant comparison have 
been reported (*=p<0.05; **=p<0.01; ***=p<0.001).  
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Figure 3  
Imaging cortical pathology in the MS study cohort. Patients were grouped based on the presence of at least 
10 CLs (TS-MShigh) or less that 2 CLs (TS-MSlow). Illustration of MRI profile representative of the T-MSlow 
group (A) and the T-MShigh subjects (B). 3D Double Inversion Recovery MRI acquisitions are reported in 
three views: axial, coronal and sagittal, respectively. CLs (red arrows) and WM lesions (green arrows) are 
highlighted. Protein expression of NF-L in the diagnostic CSF (C) taken from 26 controls (yellow bar), 15 T-
MSlow (green bar), 20 T-MShigh (red bar), 19 V-MSlow (green bar with texture) and 19 V-MShigh (red bar 
with texture) patients. Statistical analysis of the data was performed using the non parametric Mann-
Whitney test. p values for each statistically significant comparison are reported (*=p<0.05; **=p<0.01; 
***=p<0.001).  
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Figure 4  
CSF protein analysis in MS and control cohorts. Protein levels of the 18 CSF biomarkers found differentially 
expressed in the CSF of 26 controls (ctrls; yellow bar), 15 TS-MSlow (green bar), 20 TS-MShigh (red bar), 
19 VS-MSlow (green bar with texture) and 19 VS-MShigh (red bar with texture) patients. The levels of 
CXCL13, CXCL12, CCL25, TNF, sTNFR1, IFNγ, IFN-α2, IFN-λ2, IL6, IL8, IL-10, BAFF, APRIL, LIGHT, TWEAK, 
GM-CSF, MMP-2, Pentraxin3 and sCD163 were significantly increased in the CSF of the TS-MShigh and VS-
MShigh groups compared to controls (FDR < 0.05). Only the levels of IFN-α2, IFN-λ2, CCL25 were 
significantly elevated in the MSlow groups compared to both controls and MShigh groups. Significant 
increases in CXCL12, CXCL13, IFNγ, TNF, TNFR1, APRIL, LIGHT and BAFF were also observed in the CSF of 
TS-MShigh and VS-MShigh compare to TS-MSlow and VS-MSlow groups respectively. Statistical analysis of 
the data was performed using the non parametric Mann-Whitney test. p values for each statistically 
significant comparison have been reported (*=p<0.05; **=p<0.01; ***=p<0.001).  
 
Page 34 of 39
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
  
 
 
Figure 5  
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Figure 6  
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